Mayor from Ohio. (Getty image file photo.)
Each morning in the Ohio Capital Journal’s free newsletter, The Eye-Opener, we round up the news and commentary from across Ohio, the country and the world that catches our eye. We call this feature Catching Our Eye and have published it here.
Sign up for our free daily newsletter to get all the Ohio news you need to know delivered straight to your inbox every weekday morning.
If you already subscribe, please share the Ohio Capital Journal with your family and friends: https://ohiocapitaljournal.com/subscribe/
Catching our eyes
• Ohio law schools. Reuters reports: “Ohio’s proposal would limit the ABA’s role in recruiting lawyers“
Ohio is poised to eliminate the requirement that lawyers graduate from an American Bar Association-accredited law school, joining other Republican-led states in facing a backlash against the ABA’s law school oversight role under the Trump administration.
The Ohio Supreme Court on Thursday said it has directed the court’s top administrator to develop its own process for accrediting Ohio law schools and solicited public comments, opening a recent tab on changes to admissions rules that eliminate specific references to the ABA.
• Climate. Sarah Donaldson of the Statehouse News Bureau reports: “Climate activists march from southern Ohio to Columbus“
About two dozen hikers walked more than 100 miles north and then west over the past two weeks, ending the “Great Ohio Climate March” Thursday morning under blue skies in front of the Statehouse.
Under the sun and through bouts of flooding left by the rain, Great Ohio Climate March hikers traveled from Athens City Pool to Salt Fork State Park in Cambridge to downtown Columbus. At various stages of the march, they were joined by approximately 180 tourists from Ohio and elsewhere. The event was chaired by Third Law, a nationwide environmental organization of activists over 60 years of age.
• Skin cancer vaccine? NPR reports: “An anti-cancer vaccine created especially for you. mRNA is back and fighting melanoma.“
At the time, mRNA technology was in the news due to the recently developed Moderna vaccine against Covid-19. This melanoma study, which included 157 patients from Australia and the United States, all of whom had undergone surgery to remove the cancer, aimed to see whether the same mRNA technology could be used to create a personalized cancer vaccine, explains Dr. Janice Mehnert. Mehnert is a melanoma specialist and researcher at NYU Langone Health and senior author of a recent paper published Monday that examines five-year outcomes…
The results are striking. After five years of follow-up, 68.8% of patients who received the combination therapy were found to be cancer-free, compared with 49.1% of patients who received Keytruda alone, a 49% risk reduction. “It’s pretty exciting,” Mehnert says.
Additionally, 92% of patients who received the combination therapy lived for five years, compared with 71% of patients who used Keytruda alone. “I think this is strong evidence that this therapy, when used in combination with immunotherapy, can demonstrably reduce the risk of dying from this disease,” he says.
YOU MAKE OUR WORK POSSIBLE.
